Peficitinib

DB11708InvestigationalSmall molecule

Peficitinib has been used in trials studying the treatment and basic science of Psoriasis, Pharmacodynamics, Drug Interactions, Colitis, Ulcerative, and RHEUMATOID ARTHRITIS, among others.

Mechanism: Pharmacologically active on Janus (JAK) kinases
Curator reviewed
Formula / weight: C₁₈H₂₂N₄O₂ · 326.4 g/mol (avg)
Code names: ASP-015K · JNJ-54781532

Resolves to

Compound

UNIIHPH1166CKXCAS944118-01-8PubChem57928403

Clinical / RWD

ATCL04AF06

Structure

InChIKeyDREIJXJRTLTGJC-RRBRBRQDSA-NSMILESNC(=O)C1=CN=C2NC=CC2=C1N[C@H]1[C@H]2CC3C[C@@H]1C[C@@](O)(C3)C2

Targets

P23458JAK1P52333JAK3

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

362Drug interactionsStructured to mechanism, not free text

18Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 10 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Peficitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account